Posters

XEN performance in advanced glaucoma at 12 months

Poster Details

First Author: D.Lopes PORTUGAL

Co Author(s):    T. Loureiro   R. Carreira   N. Marques   I. Machado   P. Telles   N. Campos     

Abstract Details

Purpose:

To evaluate the performance of XEN® Gel Stent in the treatment of patients with advanced glaucoma at 1 year.

Setting:

Garcia de Orta Hospital.

Methods:

In this prospective interventional study, 14 eyes of patients with advanced primary open-angle or pseudoexfoliative glaucoma underwent XEN® implantation with subconjunctival mitomycin-C. Patients with advanced glaucoma under maximal therapy or intolerance to therapy were selected. Follow-up visits included intraocular pressure (IOP), number of medications, visual acuity and complications. Success was defined as IOP reduction ≥20% from preoperative baseline at 1 year on the same or fewer medications or IOP reduction between 10 and 20% at 1 year with fewer medications.

Results:

Fourteen devices were implanted but two patients were excluded for implant extrusion. At 12 months, 66.6 % met the success criteria. Mean IOP change from baseline was 21.9 %, 16.3%, 7.1% and 16.8 % at 1 week, 1 month, 3 months and 12 months (p = 0.01, 0.06, 0.38, and 0.02) respectively. Mean number of medications dropped from 3,46 ± 1.08 preoperatively to 1.55 ± 1.37 (p =0.003) at 1 year. No intraoperative complications were reported. Postoperative complications/adverse events included implant extrusion in 2 eyes, conjunctival erosion in 1 eye and needling in 3 eyes.

Conclusions:

XEN® implant allowed a significant reduction in IOP and medication, representing an effective and safe surgical treatment for advanced glaucoma, without significant major or unexpected complications.

Financial Disclosure:

None